Furthermore, this review underscores the significance of continuous STAT3 activation in promoting adenomyosis and the intriguing hypothesis that KRAS mutations could potentially serve as biomarkers for treatment efficacy, opening doors to genetically guided therapies. This evidence concerns the gene KRAS and adenomyosis.